Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136676 | 0.84 | MAPT (0.57) | ALDH1A1CYP1A2CYP2C9HPGDMAPT | |
| SCHEMBL4966461 | 0.84 | MAPT (0.62) | ALDH1A1CYP1A2CYP2C9HPGDMAPT | |
| SCHEMBL26633298 | 0.82 | MAPT (0.63) | ALDH1A1CYP1A2CYP2C9HPGDPOLB | |
| SCHEMBL3567484 | 0.79 | SIRT6 (0.56) | ALDH1A1CYP1A2CYP2C9HPGDMAPT | |
| SCHEMBL341002 | 0.79 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C9HPGDPOLB | |
| SCHEMBL3440200 | 0.78 | POLB (0.53) | ALDH1A1CYP1A2CYP2C9HPGDPOLB | |
| SCHEMBL4675601 | 0.76 | ALDH1A1 (0.74) | ALDH1A1CYP1A2CYP2C9HPGDPOLB | |
| SCHEMBL10413396 | 0.76 | POLB (0.62) | ALDH1A1POLBKMT2AHTTKDM4E | |
| SCHEMBL19283722 | 0.76 | KMT2A (0.43) | ALDH1A1CYP1A2CYP2C9HPGDPOLB | |
| SCHEMBL1126466 | 0.76 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C9HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024201308-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | 주식회사 엘지화학 | 2024-10-03 | — | — | WO | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014111037-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海昀怡健康管理咨询有限公司 (CN) | 2014-07-24 | — | — | WO | disclosed |
| EP-2696683-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | Alzheimer's Institute of America, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | ALDH1A1 1105/4885CYP1A2 1666/4885CYP2C9 2189/4885 |
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | ALDH1A1 2440/4885CYP1A2 629/4885CYP2C9 470/4885 |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885CYP1A2 3038/4885CYP2C9 4047/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | ALDH1A1 4487/4885CYP1A2 4860/4885CYP2C9 4879/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885CYP1A2 3038/4885CYP2C9 4047/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885CYP1A2 3038/4885CYP2C9 4047/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885CYP1A2 3038/4885CYP2C9 4047/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885CYP1A2 3038/4885CYP2C9 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.